May 11, 2018 Kringle Pharma announces that the last subject has completed the follow-up period after dosing in the Phase I/II study of recombinant human HGF for acute spinal cord injury.

February 27, 2018 A patent entitled 'HGF preparation suitable for treatment of nervous diseases' was granted in Japan. Patent No. JP6281992.

January 10, 2018 Clinical data from the investigator-initiated Phase I/II of recombinant human HGF for treatment of vocal fold scar were published in Journal of Tissue Engineering and Regenerative Medicine (25 DEC 2017, DOI: 10.1002/term.2603). It was demonstrated that intracordal injection of the recombinant human HGF drug was safe, feasible, and potentially effective for vocal fold scar patients based on several evaluation methods.

December 22, 2017 New board members were selected at the 16th general shareholders meeting, and the board members appointed Kiichi Adachi as President and CEO.
December 22, 2017 Kringle Pharma announces completion of participant enrollment in the Phase I/II study of recombinant human HGF for acute spinal cord injury.
Click Here For More Info.[pdf] (138KB)
Copyright (C)2004-2011 Kringle Pharma, Inc. All rights reserved.